"Bronchodilator Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
| Descriptor ID |
D001993
|
| MeSH Number(s) |
D27.505.696.663.050.110 D27.505.954.796.050.100
|
| Concept/Terms |
Bronchodilator Agents- Bronchodilator Agents
- Agents, Bronchodilator
- Bronchial-Dilating Agents
- Agents, Bronchial-Dilating
- Bronchial Dilating Agents
- Bronchodilators
Broncholytic Effect- Broncholytic Effect
- Effect, Broncholytic
- Broncholytic Effects
- Effects, Broncholytic
Bronchodilator Effect- Bronchodilator Effect
- Effect, Bronchodilator
- Bronchodilator Effects
- Effects, Bronchodilator
|
Below are MeSH descriptors whose meaning is more general than "Bronchodilator Agents".
Below are MeSH descriptors whose meaning is more specific than "Bronchodilator Agents".
This graph shows the total number of publications written about "Bronchodilator Agents" by people in this website by year, and whether "Bronchodilator Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2005 | 5 | 3 | 8 |
| 2006 | 3 | 0 | 3 |
| 2007 | 7 | 1 | 8 |
| 2008 | 6 | 2 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 6 | 12 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 5 | 7 |
| 2014 | 2 | 3 | 5 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 4 | 2 | 6 |
| 2018 | 8 | 1 | 9 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 2 | 7 | 9 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bronchodilator Agents" by people in Profiles.
-
POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes. Chest. 2024 Jul; 166(1):12-17.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
-
Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong. Respir Med. 2024 02; 222:107516.
-
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection. Influenza Other Respir Viruses. 2023 12; 17(12):e13231.
-
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
-
Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
-
EMS Administration of Systemic Corticosteroids to Pediatric Asthma Patients: An Analysis by Severity and Transport Interval. Prehosp Emerg Care. 2023; 27(7):900-907.
-
Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
-
Asthma Care Protocol Implementation in the Pediatric Intensive Care Unit. Crit Care Nurs Clin North Am. 2023 Sep; 35(3):337-346.
-
Beta Agonists for Prevention of Respiratory Adverse Events in Children Undergoing Adenotonsillectomy: Long-Acting, Short Acting, or Not Acting. Anesth Analg. 2023 06 01; 136(6):1064-1066.